Short answer

When developing solutions in complex or data-scarce environments, prioritize systematic evidence appraisal, stakeholder engagement, and a focus on minimizing negative side effects, while advocating for further research into user outcomes and economic viability.

Field
Commercial Production
Source
Blood Advances (2019)
Method
Guideline development using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and evidence-to-decision frameworks.
Evidence
Moderate effect

Developing evidence-based guidelines, even with limited randomized trial data, can significantly improve decision-making for complex medical conditions by synthesizing expert knowledge and patient perspectives. This commercial production research insight is drawn from a 2019 study published in Blood Advances. Using Guideline development using the grading of recommendations assessment, development and evaluation (grade) approach and evidence-to-decision frameworks., researchers explored how this design variable affects real-world outcomes. The key design takeaway: When developing solutions in complex or data-scarce environments, prioritize systematic evidence appraisal, stakeholder engagement, and a focus on minimizing negative side effects, while advocating for further research into user outcomes and economic viability.

Study
Commercial ProductionHigh ImpactModerate effect

Evidence-Based Guidelines Optimize Treatment Pathways for Immune Thrombocytopenia

Developing evidence-based guidelines, even with limited randomized trial data, can significantly improve decision-making for complex medical conditions by synthesizing expert knowledge and patient perspectives.

Blood Advances · 2019

01

Key Findings

  • 01There was a lack of evidence to support strong recommendations for various management approaches.
  • 02Strategies that avoided medication side effects were generally favored.
  • 03Shared decision-making was emphasized, particularly for second-line therapy.
02

Application

Design takeaway

When developing solutions in complex or data-scarce environments, prioritize systematic evidence appraisal, stakeholder engagement, and a focus on minimizing negative side effects, while advocating for further research into user outcomes and economic viability.

How to apply

When designing a new product or system where direct comparative data is scarce, create a decision matrix that weighs potential benefits against risks and side effects, and incorporate mechanisms for user feedback and shared decision-making.

Project actions

  • 01When researching a design problem, look for existing guidelines or best practices, even if they are from different fields.
  • 02Consider how to involve potential users in the decision-making process for your design.
03

Method & Evidence

AimTo develop evidence-based guidelines for the management of immune thrombocytopenia (ITP) to support clinical decision-making.
MethodGuideline development using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and evidence-to-decision frameworks.
ProcedureA multidisciplinary panel reviewed existing guidelines, prioritized questions, appraised evidence up to May 2017, and formulated 21 recommendations for managing adult and pediatric ITP across different disease stages.
ContextMedical treatment guidelines for immune thrombocytopenia (ITP).

Variables

IVMultidisciplinary panel composition, use of GRADE approach, evidence appraisal.
DVNumber and type of recommendations, emphasis on shared decision-making, favored management strategies.
CVFocus on ITP management, timeframe of evidence review.
04

Strengths & Limitations

Strengths

  • +Multidisciplinary expert panel.
  • +Systematic evidence appraisal using GRADE.
  • +Inclusion of patient representatives.

Limitations

The guidelines are specific to ITP and may not directly translate to other design contexts. The evidence base was limited at the time of publication.

Reliability & validity

The reliability of the guidelines stems from the systematic review process and the consensus-driven approach of the panel. Validity is supported by the use of established frameworks like GRADE, though the limited empirical data for ITP itself might affect the strength of recommendations.

Think critically

How can the principles of evidence-based guideline development be adapted to inform the design of products or services in rapidly evolving technological fields where empirical data is inherently scarce?

05

Design Principles

"In the absence of definitive data, prioritize solutions that minimize harm and maximize user agency, supported by a structured, evidence-informed decision-making process."

This approach is crucial in design practice when facing novel challenges or areas with sparse empirical data. By systematically reviewing existing knowledge, incorporating diverse stakeholder input, and employing structured evaluation frameworks, designers can create robust frameworks for decision-making and product development.

06

What This Means for Your Design

Even when there isn't a lot of perfect information, experts can come together to create the best possible advice for making decisions, focusing on what's safest and involving the people affected.

How to use in your project

  • 1.Reference the process of guideline development as an example of synthesizing information and making recommendations in a complex field.
  • 2.Use the emphasis on shared decision-making to inform your user research and design iteration phases.
07

Add to My Project

08

Quick Cite

Paragraph starter

The development of evidence-based guidelines for immune thrombocytopenia, as outlined by the American Society of Hematology, demonstrates a robust methodology for decision-making in complex domains with limited empirical data. This approach, utilizing frameworks like GRADE and incorporating multidisciplinary expert and patient input, prioritizes minimizing adverse effects and fostering shared decision-making. This serves as a valuable model for design projects facing similar challenges, emphasizing systematic evidence appraisal and user-centric considerations.

09

Source

Blood Advances

American Society of Hematology 2019 guidelines for immune thrombocytopenia

journal · 2019

View source

Questions About This Research

What does the research say about evidence-based guidelines optimize treatment pathways for immune thrombocytopenia?
When developing solutions in complex or data-scarce environments, prioritize systematic evidence appraisal, stakeholder engagement, and a focus on minimizing negative side effects, while advocating for further research into user outcomes and economic viability. Evidence: Blood Advances (2019).
Why does "Evidence-Based Guidelines Optimize Treatment Pathways for Immune Thrombocytopenia" matter for design?
This approach is crucial in design practice when facing novel challenges or areas with sparse empirical data. By systematically reviewing existing knowledge, incorporating diverse stakeholder input, and employing structured evaluation frameworks, designers can create robust frameworks for decision-making and product development.
How can designers apply this research?
When developing solutions in complex or data-scarce environments, prioritize systematic evidence appraisal, stakeholder engagement, and a focus on minimizing negative side effects, while advocating for further research into user outcomes and economic viability.
What were the main findings?
There was a lack of evidence to support strong recommendations for various management approaches.. Strategies that avoided medication side effects were generally favored.. Shared decision-making was emphasized, particularly for second-line therapy.
What research method was used?
Guideline development using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and evidence-to-decision frameworks..
How strong is the evidence?
Evidence strength is rated Moderate effect, based on a 2019 journal from Blood Advances.
What should I do differently in my next project?
When designing a new product or system where direct comparative data is scarce, create a decision matrix that weighs potential benefits against risks and side effects, and incorporate mechanisms for user feedback and shared decision-making.
What are the limitations?
Limited data from randomized trials, potential for bias in expert opinion.